997 reports of this reaction
1.8% of all DASATINIB reports
#13 most reported adverse reaction
PULMONARY OEDEMA is the #13 most commonly reported adverse reaction for DASATINIB, manufactured by E.R. Squibb & Sons, L.L.C.. There are 997 FDA adverse event reports linking DASATINIB to PULMONARY OEDEMA. This represents approximately 1.8% of all 55,495 adverse event reports for this drug.
DASATINIB has an overall safety score of 82 out of 100. Patients taking DASATINIB who experience pulmonary oedema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY OEDEMA is a less commonly reported adverse event for DASATINIB, but still significant enough to appear in the safety profile.
In addition to pulmonary oedema, the following adverse reactions have been reported for DASATINIB:
The following drugs have also been linked to pulmonary oedema in FDA adverse event reports:
PULMONARY OEDEMA has been reported as an adverse event in 997 FDA reports for DASATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY OEDEMA accounts for approximately 1.8% of all adverse event reports for DASATINIB, making it a notable side effect.
If you experience pulmonary oedema while taking DASATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.